ストックスクリーナーアプリを入手
19.02
2.42%
0.45
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Arrowhead Pharmaceuticals (ARWR) Set to Announce Earnings on Tuesday - MarketBeat
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - BioSpace
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 6.3%Here's What Happened - MarketBeat
When (ARWR) Moves Investors should Listen - Stock Traders Daily
Privium Fund Management B.V. Has $6.46 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Leerink Partnrs Has Positive Outlook of ARWR FY2024 Earnings - MarketBeat
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - BioSpace
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - BioSpace
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - BioSpace
abrdn plc Has $7.77 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Launches FCS Awareness Campaign - Baystreet.ca
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, 'We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Quantisnow
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaig - GuruFocus.com
In the wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest US$108m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St
International Assets Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
(ARWR) Long Term Investment Analysis - Stock Traders Daily
Assenagon Asset Management S.A. Has $5.68 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $45.33 - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4%Here's Why - MarketBeat
(ARWR) Trading Signals - Stock Traders Daily
Buffington Mohr McNeal Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - MarketBeat
State Street Corp's Strategic Acquisition in Arrowhead Pharmaceu - GuruFocus.com
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - GlobeNewswire
Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma - The Globe and Mail
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 14, 2024 - BioSpace
HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (STU:HDP1) EV-to-Revenue : 93.89 (As of Oct. 11, 2024) - GuruFocus.com
Dimensional Fund Advisors LP Boosts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highl - GuruFocus.com
Arrowhead Pharmaceuticals Plans $250M Manufacturing Plant in Wisconsin - Pasadena Now
How to Take Advantage of moves in (ARWR) - Stock Traders Daily
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Overweight Rating at Piper Sandler - MarketBeat
Goldman Sachs holds Neutral rating on Arrowhead stock By Investing.com - Investing.com Canada
Arrowhead Pharma maintains Buy rating from TD Cowen after R&D day insights - Investing.com Canada
Arrowhead Pharma retains Overweight rating from Piper Sandler By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year LowShould You Sell? - MarketBeat
ARWR stock touches 52-week low at $18.14 amid market challenges - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Millennium Management LLC - MarketBeat
Bank of Montreal Can Buys 30,866 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment? - Simply Wall St
Arrowhead: A First Approval LikelyJury Still Out On Investment Opportunity (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low at $18.61 - MarketBeat
Severe Hypertriglyceridemia Market Growth to Accelerate - openPR
Severe Hypertriglyceridemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, 89bio, Inc., Arrowhead Pharma, Hightide Therapeutics, AstraZeneca, Kowa - Barchart
Squarepoint Ops LLC Invests $9.98 Million in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
(ARWR) Investment Analysis and Advice - Stock Traders Daily
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):